Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low Risk Myelodysplastic Syndrome”

238 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 238 results

Post-approval studies (Phase 4)Study completedNCT03598582
What this trial is testing

Biological Predictive Factors of Response to ESA in Low Risk MDS Patients

Who this might be right for
Myelodysplastic Syndromes
Association pour la recherche sur les Affections Malignes en Immunologie Sanguine 70
Testing effectiveness (Phase 2)Study completedNCT00551291
What this trial is testing

NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Who this might be right for
Myelodysplastic Syndromes
Hoffmann-La Roche 10
Testing effectiveness (Phase 2)Ended earlyNCT00840827
What this trial is testing

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome
Weill Medical College of Cornell University 6
Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Ended earlyNCT00699842
What this trial is testing

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8
Not applicableApproved For MarketingNCT05937568
What this trial is testing

Expanded Access for Treatment With Imetelstat

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation
Testing effectiveness (Phase 2)Study completedNCT00382590
What this trial is testing

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
M.D. Anderson Cancer Center 11
Large-scale testing (Phase 3)UnknownNCT04324060
What this trial is testing

Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Who this might be right for
Low/Intermediate Risk-1 MDS
Peking Union Medical College Hospital 75
Early research (Phase 1)Study completedNCT00916227
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 45
Testing effectiveness (Phase 2)Study completedNCT01081431
What this trial is testing

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 91
Testing effectiveness (Phase 2)Ended earlyNCT00074490
What this trial is testing

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Who this might be right for
LymphomaLeukemiaMyeloproliferative Disorders+2 more
National Cancer Institute (NCI) 442
Large-scale testing (Phase 3)Looking for participantsNCT07422480
What this trial is testing

Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic SyndromeAnemia
Takeda 300
Large-scale testing (Phase 3)Ended earlyNCT03263091
What this trial is testing

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Who this might be right for
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia
Kyntra Bio 184
Testing effectiveness (Phase 2)Ended earlyNCT02928419
What this trial is testing

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Who this might be right for
Myelodysplastic Syndromes
Associazione Qol-one 2
Not applicableLooking for participantsNCT02269592
What this trial is testing

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic SyndromesHematological Malignancies+5 more
Dana-Farber Cancer Institute 10,000
Early research (Phase 1)Study completedNCT02038777
What this trial is testing

PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Pfizer 48
Early research (Phase 1)Ended earlyNCT01362036
What this trial is testing

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Tarix Pharmaceuticals 2
Early research (Phase 1)WithdrawnNCT04176653
What this trial is testing

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Who this might be right for
Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic Syndrome
Silence Therapeutics plc
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Post-approval studies (Phase 4)Study completedNCT02145026
What this trial is testing

Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Hoffmann-La Roche 100
Load More Results